CTIS2022-500230-28-00招募中1 期
A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment - 20-HMedIdeS-21
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Signed Informed Consent obtained from patient/parent/legal guardian/independent witness (depending on patient’s age) before any trial-related procedures, Highly sensitised patient with panel reactive antibodies (PRA) =80%, Male of female patient between the age of 1 to 17 years (up to the day before the 18th birthday) at the time of screening, Patient with end-stage renal disease (ESRD) and waiting for a renal transplant from a living or deceased donor, Patient must be transplantable (including size mismatch) at the time of obtaining informed consent for trial participation, Patients who have previously undergone desensitisation unsuccessfully with plasmapheresis/IVIg/anti-CD20 or have an anti-HLA antibody status deemed too difficult to make a successful desensitisation (judgement based on physicians’ previous experience with similar patients), Positive crossmatch test determined by FCXM and/or CDCXM tests against the donor. For the DD patients, if physical crossmatch tests are not practically possible due to lack of time, patients may be included on a vXM predictive of a positive crossmatch test., Willingness and ability to comply with the protocol as judged by the investigator
排除标准
- •Previous treatment with imlifidase, Any other reason that, in the view of the investigator, precludes transplantation, Breast feeding or pregnancy, if applicable, Woman of fertile age and sexually active without adequate contraceptive measures to avoid pregnancy during the interventional trial period (i.e. up to 6 months after transplantation), Suspicion of Covid-19 infection or positive SARS-CoV-2 test, Positive serology for human immunodeficiency virus (HIV), Clinical signs of hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein Barr virus (EBV) infection, Donor with positive serology for HIV, HBV, HCV, CMV or EBV to a patient with negative serology (mismatch serology), Clinically relevant active infection(s) as judged by the investigator, Tuberculosis, Use of other investigational agents within 5 terminal elimination half-lives prior to the transplantation, IVIg treatment within 28 days prior to imlifidase treatment, Contemporaneous participation in medical device studies, Known mental incapacity or language barriers precluding patients’/parents’/legal guardians’ adequate understanding of the informed consent information and the trial activities, Inability by the judgement of the investigator to participate in the trial for any other reason, Desensitisation treatment(s) within 1 month prior to the current transplantation, Hypersensitivity to the active substance (imlifidase) or to any of the excipients and to other immunosuppressive drugs specified in the protocol, Ongoing serious infections, Present, or history of, thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP, At the time of transplantation: severe other condition requiring treatment and close monitoring e.g. cardiac failure = grade 4 (New York Heart Association), unstable coronary disease, active peripheral vascular disease, proven hypercoagulable conditions/events or oxygen dependent respiratory disease, Malignancy within 3 years prior to transplantation, ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
研究者
相似试验
尚未招募
不适用
A single arm, Multicenter study evaluating efficacy of beta 2-microglobulin adsorption column on dialysis-related amyloidosisEnd-stage renal disease, Dialysis-related amyloidosisJPRN-UMIN000031418Hirosaki University School of Medicine30
尚未招募
不适用
Comparative clinical study of eye drops in dry eye syndromeDiseases of the eye and adnexaKCT0004516Kangbuk Samsung Medical Center60
招募中
2 期
Remdesivir in treatment of COVID-19IRCT20171122037571N2Tehran University of Medical Sciences120
进行中（未招募）
1 期
Multicentre clinical trial to evaluate the efficacy and safety of dexketoprofen trometamol (50 mg t.i.d.) versus ketorolac (30 mg t.i.d.) and placebo by intravenous route, as part of balanced analgesic therapy with morphine, followed by an oral dosing, in the treatment of postoperative paielective orthopedic surgery (hip arthroplasty)MedDRA version: 7.0Level: PTClassification code 10020096EUCTR2004-001373-26-ESaboratorios Menarini, S.A
招募中
不适用
A study of apalutamide in metastatic castration-resistant prostate cancer patientsMetastatic Castration-resistant Prostate CancerJPRN-jRCTs051220077akano Yuzo110